The FDA instituted clinical trials to explore the possibility of cardiac problems associated with taking this drug; however, during these trials, the issue of lower-body amputations became a focus. The clinicians found that patients taking Invokana were twice as likely to suffer either a leg or foot amputation as the patients taking a placebo. This translates to seven of every 1,000 patients taking 100 mg daily and five of every 1,000 patients who took 300 mg daily, compared to three of every 1,000 patients who took a placebo. The most common amputations from gangrene are toe amputations, and parts of the middle of the foot. Precursors to amputations include tenderness in the legs and feet, sores, ulcers and infections. If you experienced a below-the-knee amputation as a result of ingesting this drug before May 16, 2017, you may be able to file a claim against Janssen.
Because the drug focuses on the kidney, inhibiting its ability to absorb glucose into the bloodstream, there are risks associated with kidney failure. When kidneys no longer start working properly, then the body’s waste products and fluids build up, resulting in kidney failure. When sugar is present in urine, there is a higher risk of contracting a urinary tract infection, which can spread to the bloodstream and damage the kidneys further. Symptoms include weakness, shortness of breath, lethargy, cardiac arrhythmia and even sudden death.
This is a common medical condition with individuals suffering from diabetes. The condition develops when not enough insulin is produced, whereby the body has to break down fat for energy instead. This causes a toxic build of ketones in the bloodstream. High levels of ketones are produced in the body, which can result in a diabetic coma, hospitalization, or death. In SGLT2 inhibitors, extra glucose is pushed out through urine. Typically, the kidney cannot handle that much excess glucose. They become overworked and shut down, leading to the backup of your body’s waste back into your bloodstream. If you have suffered from ketoacidosis that resulted in hospitalization and you took one of these SGLT2 inhibitors before December 4, 2015, you might be entitled to compensation.
Current Lawsuits: Bellwether Trials 2018
Right now, the case is still in its pre-trial discovery phase, with bellwether trials slated to begin in September 2018. Bellwether trials are initial trials selected by the parties in MDLs which give the parties an idea of how the rest of the cases might go. This is helpful in determining settlement options. So, if the plaintiffs are awarded a massive financial verdict, then the drug company will be incentivized to minimize their exposure and reach reasonable settlements against the claimants. These trials are also useful in determining what kind of evidence and testimony the courts will accept or find persuasive.
There will potentially be 12 bellwether cases in total which represent each kind of injury asserted as selected by plaintiffs and defendants, who will get to choose six cases. Out of this 12, the judge will choose three cases for the first trials. The only people who can be in the bellwether trial are those individuals who filed a claim before July 31, 2017 and have been prescribed Invokana.